Roivant Sciences Ltd.

ROIV

$38.22

Updated: 23/09/2026, 14:33:03

Market Cap

$27.61B

Sector

Healthcare

Industry

Biotechnology

Country

Stock valuation chart

One-year closing share-price history for ROIV

Company Profile

Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.

USD

NASDAQ

CEO: Matthew Gline

Employees: 721

https://roivant.com

Asset Summaries

Latest generated summaries for ROIV

No summaries found.

Detailed business

Structured knowledge from the latest official annual filing.

No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.

Full company information

Latest profile, trading, valuation, and identifier data stored for ROIV.

Share price: $38.22
Market cap: $27.61B
Exchange: NASDAQ
Currency: USD
CEO: Matthew Gline
Employees: 721
IPO date: 08/12/2020
Beta: 1.122
Last dividend: $0.00
Day range: $38.11 – $39.13
52-week range: $14.50 – $42.50
1-day performance: -1.97%
1-year performance: 163.59%
Current drawdown (1Y): -10.07%
CIK: 0001635088
CUSIP: G76279101
ISIN: BMG762791017
Created: 07/12/2025, 14:02:01
Last update: 23/09/2026, 14:33:03

Track Roivant Sciences Ltd. with an AI analyst

See which prediction-market events move ROIV, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Create a free account See what the world decides next

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News

News linked to ROIV from your Railway `news_articles` table.

Roivant Sciences Ltd. (ROIV) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 09/06/2026, 22:22:12

Roivant Sciences Ltd. (ROIV) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 03/06/2026, 20:32:01

Roivant Sciences Ltd. (ROIV) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript

Seeking Alpha • STOCK • 29/05/2026, 19:24:06

Roivant Sciences Ltd. (ROIV) Q4 2025 Earnings Call Transcript

Seeking Alpha • STOCK • 20/05/2026, 20:20:55

Roivant Sciences Q4 Earnings Call Highlights

MarketBeat • STOCK • 20/05/2026, 12:08:42

Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates

Zacks Investment Research • STOCK • 20/05/2026, 11:15:12

Montes Archimedes Acquisition (ROIV) Upgraded to Buy: Here's Why

Zacks Investment Research • STOCK • 19/05/2026, 15:01:16

Roivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 13/05/2026, 18:50:45

Montes Archimedes Acquisition (ROIV) Upgraded to Buy: Here's What You Should Know

Zacks Investment Research • STOCK • 10/04/2026, 15:00:47

Roivant Sciences Ltd. (ROIV) Discusses Brepocitinib Program Expansion and Phase III Batoclimab Data Update Transcript

Seeking Alpha • STOCK • 02/04/2026, 18:32:04

Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)

GlobeNewsWire • STOCK • 02/04/2026, 07:00:00

New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis

GlobeNewsWire • STOCK • 28/03/2026, 16:00:00